Ketones vs. MS: Can a Ketogenic Diet Rewire the Future of Multiple Sclerosis? For Multiple Sclerosis Awareness Month, we explore a radical but evidence-backed nutritional approach that may alter the course of MS — the ketogenic diet.

What is MS and Why Are We Still Struggling to Treat It?

Multiple Sclerosis (MS) is a chronic autoimmune condition where the immune system attacks the central nervous system (CNS), specifically the myelin sheath protecting nerve fibers. This leads to widespread neuroinflammation, demyelination, axonal injury, and eventually neurodegeneration.

Globally, MS affects over 2.8 million people, predominantly young adults, with higher incidence in women[^1]. Symptoms vary but often include fatigue, visual disturbances, numbness, muscle weakness, cognitive dysfunction, and loss of coordination.Conventional treatment strategies, such as disease-modifying therapies (DMTs), attempt to reduce relapses and delay progression. Yet, they fall short in reversing neurological decline and often carry significant side effects[^2]. As MS is increasingly recognized as a disease driven by metabolic and inflammatory dysfunction, researchers are looking beyond pharmaceuticals and into food.

MS: A Disease of Immunity, Inflammation, and Metabolism Gone Wrong

The pathogenesis of MS is multifactorial, involving:

• Autoimmune dysregulation, with overactive Th1 and Th17 responses
• Oxidative stress and mitochondrial dysfunction
• Disrupted lipid metabolism and insulin signaling
• Alterations in the gut microbiota[^3,^4]

Recent studies also emphasize a metabolically stressed CNS and a shift toward neurodegenerative mechanisms even in early disease stages[^5]. Mitochondrial energy failure, reactive oxygen species (ROS), and chronic glial activation further damage neurons and prevent remyelination[^6].

Adding to the complexity, people with MS often have gut dysbiosis — a loss of beneficial, anti-inflammatory microbial species and increased gut permeability — which may exacerbate systemic inflammation and CNS autoimmunity[^7,^8].

How a Ketogenic Diet Targets the Roots of MS

A ketogenic diet (KD) is a high-fat, very low-carbohydrate nutritional intervention that induces the production of ketone bodies like beta-hydroxybutyrate (BHB). These molecules are not just fuel — they’re powerful signaling agents that influence inflammation, energy metabolism, and brain health.

Here’s how KD may counter MS pathology:

• Reduces neuroinflammation: BHB inhibits the NLRP3 inflammasome, a key driver of neuroinflammatory damage in MS[^9].
• Restores energy metabolism: KD improves mitochondrial efficiency and ATP production, critical in MS where neurons are energy-starved[^3,^6].
• Protects myelin and neurons: By reducing oxidative stress and excitotoxicity, ketones help preserve CNS integrity[^5].
• Improves gut health: KD has been shown to repopulate beneficial bacteria, reduce gut permeability, and modulate immune function[^7,^8].
  
  The metabolic and immunomodulatory effects of KD align remarkably well with the known disruptions in MS — making it a biologically plausible adjunctive therapy.

What Do Preclinical Models Say? Powerful Results in Animal Studies

Animal and cell culture studies have repeatedly demonstrated that ketogenic diets benefit experimental models of MS:

• In mouse models of experimental autoimmune encephalomyelitis (EAE), KD delayed disease onset, reduced symptom severity, and promoted remyelination and neuronal survival[^3].
• KD also reduced infiltration of inflammatory immune cells into the CNS and supported a more balanced T cell profile, increasing regulatory T cells while decreasing pro-inflammatory Th17 cells[^4].
• Metabolically, KD corrected dysfunctional lipid and mitochondrial pathways, directly improving neuroglial resilience[^5].

These studies indicate KD may not only slow disease but reverse some of the cellular damage associated with MS.

Clinical Evidence: Small but Promising Steps Forward

Clinical trials are still in their infancy, but early findings suggest meaningful improvements:

• In a 6-month clinical study, 65 patients with relapsing MS followed a ketogenic diet, leading to significant improvements in body composition, fatigue, depression, and quality of life, with excellent tolerability[^1].
  
• Another randomized pilot trial demonstrated that KD reduced perceived disability, improved mental health, and stabilized pro-inflammatory biomarkers[^2].
  
• A recent systematic review concluded that nutritional ketosis may modulate disease activity, reduce neuroinflammation, and support energy homeostasis in people with MS — urging further large-scale trials[^10].
  

Importantly, these benefits appear to be multi-dimensional — spanning mood, energy levels, immune markers, and even body composition.

Conclusion: A Ketogenic Diet Offers Real Therapeutic Promise for MS

Multiple Sclerosis remains an incurable disease — but that doesn’t mean we’re powerless. With its multi-targeted impact on inflammation, energy metabolism, immune regulation, and gut health, a ketogenic diet offers a new and promising frontier in MS care.

View Ketogenic Training Here

While more long-term and large-scale trials are needed, the preclinical and early clinical evidence is robust enough to justify integrating KD into comprehensive MS management — particularly for motivated patients under clinical supervision.

As we mark MS Awareness Month, let’s not just raise awareness — let’s raise the bar on what’s possible in treatment.

---

References

1. Brenton JN, Banwell B, Yeh EA, et al. Pilot study of a ketogenic diet in relapsing–remitting MS. Mult Scler Relat Disord. 2023;69:104446. https://www.sciencedirect.com/science/article/pii/S2161831323000534
   
2. Bock M, Pottgen J, Voigt I, et al. Ketogenic diet in multiple sclerosis: A randomized pilot trial. Nutr Neurosci. 2021;24(9):638–650. https://akjournals.com/view/journals/1886/13/2/article-p29.xml
   
3. Rinninella E, et al. Study protocol: Ketogenic diet in MS (KEMSMuS trial). Trials. 2020;21:56. https://link.springer.com/article/10.1186/s13063-019-3928-9
   
4. Paoli A, et al. Ketogenic diet effects on gut microbiota and immune modulation in MS. Nutrients. 2019;11(5):1156. https://www.mdpi.com/2072-6643/11/5/1156
   
5. Campbell GR, Mahad DJ. Metabolic dysfunction in progressive MS. J Neurol Neurosurg Psychiatry. 2022;93(6):637–645. https://jnnp.bmj.com/content/93/6/637.abstract
   
6. Mahad D, Ziabreva I, Campbell G, et al. Mitochondrial changes in axons and glia in MS. PLoS One. 2012;7(3):e35476. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035476
   
7. Jangi S, Gandhi R, Cox LM, et al. Altered gut microbiome in MS patients. Front Microbiol. 2017;8:1261. https://www.frontiersin.org/articles/10.3389/fmicb.2017.01141/full
   
8. Cignarella F, Cantoni C, Ghezzi L, et al. Intermittent fasting modulates microbiota and MS-like disease. Front Microbiol. 2017;8:315. https://www.frontiersin.org/articles/10.3389/fmicb.2017.01141/full
   
9. Poff AM, et al. Ketone supplementation reduces CNS inflammation and oxidative stress in vivo. Front Nutr. 2023;10:1227431. https://www.frontiersin.org/articles/10.3389/fnut.2023.1227431/full
   
10. Riccio P, Rossano R. Diet and MS: review of potential nutritional strategies. Lancet Neurol. 2018;7(6):703–718. https://www.thelancet.com/article/S2352-3964(18)30355-4/fulltext